EHA 2022 | Updates on chemotherapy-free treatment approaches for APL

Harinder Gill • 13 Jun 2022

EHA 2022

Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, talks on the development of chemotherapy-free approaches for the treatment of acute promyelocytic leukemia (APL). Dr Gill explains that arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA) is approved by the FDA for the first-line treatment of patients with APL. However, Dr Gill notes how this therapeutic approach is limited to patients with a low white blood cell (WBC) count at diagnosis and questions whether chemotherapy could be completely eradicated in high-risk APL patients or those with a high WBC count. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Novartis Oncology – honoraria, consultancies; Celgene/bms – research grant, honoraria, consultancies; PharmaEssentia – research grant; Abbvie – honoraria, consultancies; Takeda – honoraria; Pfizer Oncology – honoraria, consultant